Recycled Elastomers Market Size Hit US$ 6.8 Billion by 2026
/
Date23 Oct 2019
Email Print Friendly Share LOS ANGELES, Oct. 22, 2019 (GLOBE NEWSWIRE) — Acumen Research and Consulting, Recently Published Report On “Recycled Elastomers Market (Raw Material:... Read More →
Integra Resources SEDAR Files NI 43-101 Technical Report for the DeLamar Project Preliminary Economic Assessment
/
Date23 Oct 2019
Email Print Friendly Share Preliminary Economic Assessment Highlights: After-tax NPV (5%) of C$472 million (US$358 million) and 43% After-Tax IRR at US$1350/oz Au and US$16.90... Read More →
High Arctic Declares Monthly Dividend
/
Date23 Oct 2019
Email Print Friendly Share NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION... Read More →
Euronet Worldwide Reports Third Quarter 2019 Financial Results
/
Date23 Oct 2019
Email Print Friendly Share LEAWOOD, Kan., Oct. 22, 2019 (GLOBE NEWSWIRE) — Euronet Worldwide, Inc. (“Euronet” or the “Company”) (NASDAQ: EEFT), a leading electronic payments... Read More →
ISRAMCO, INC. STOCKHOLDERS VOTE TO APPROVE MERGER
/
Date23 Oct 2019
Email Print Friendly Share HOUSTON, TX, Oct. 22, 2019 (GLOBE NEWSWIRE) — Isramco, Inc. (NASDAQ CM: ISRL) (“Isramco” or the “Company”), announced today that at... Read More →
TNS Partners With Leading Growth Marketing Agency Crowdcreate to Energize Digital Names Brand
/
Date23 Oct 2019
Email Print Friendly Share New York, NY, Oct. 22, 2019 (GLOBE NEWSWIRE) — (via Blockchain Wire) The increasing buzz around Digital Names is about to get... Read More →
患者来源肿瘤类器官药物开发平台正式推出
/
Date23 Oct 2019
Email Print Friendly Share 圣迭戈, Oct. 23, 2019 (GLOBE NEWSWIRE) — Crown Bioscience今天宣布推出一个新的肿瘤类器官药物开发平台,有望显著提高临床前药物研发的预测性和速度。 该平台的初始阶段提供了首个市场有售的三维体外PDX源性类器官(PDXO)模型,由CrownBio超过2500多个人源肿瘤异体移植(PDX)模型组成的独特特征模型库所生成。 PDXO在生物学上相当于具有高度预测性的体内PDX模型,两者都是癌症干细胞驱动疾病模型。PDXO的额外优势是体外系统固有的速度 和可扩展性,极其适合高通量、大规模筛选和同时对多个组合策略进行测试。 这些3D 体外 模型的开发采用源自Clevers实验室的同类最佳Hubrecht类器官技术(HUB)协议,保证了鲁棒性和可靠的可转化性。CrownBio获得了HUB的独家许可,可使用HUB的类器官技术提供临床前肿瘤药物开发和验证服务。 首先推出的PDXO模型涵盖10多种癌症类型。作为平台的第二阶段,HUB患者源性类器官(PDO)将于2020年第一季度通过CrownBio独 家提供。 “在CrownBio,我们率先开发了人源肿瘤移植模型,”CrownBio首席科学官Henry Li博士表示。“我们的新样本库中包括经完善描述和注释的类器官和相匹配的体内PDX模型,为临床前药物的发现提供了一个前所未有的转化工作流。从 体外 到体内... Read More →
Galileo Acquisition Corp. Announces Closing of $138 Million Initial Public Offering
/
Date23 Oct 2019
Email Print Friendly Share New York, NY, Oct. 22, 2019 (GLOBE NEWSWIRE) — Galileo Acquisition Corp. (NYSE: GLEO.U, the “Company”) announced today that it closed... Read More →